Welcome to the Working Group on New TB Drugs Blog
TB R&D Weekly Update: Expanding Our Options for TB Treatment
For this week’s update, we will highlight three recent articles that look at repurposing and optimizing drugs already on the market or looking at novel targets and drug classes for TB. Additional links to TB R&D news are included.
TB R&D Update: 243rd American Chemistry Society Conference
The 243rd American Chemistry Society National Meeting and Exposition is being held in San Diego, California, from March 26 to March 29. There are several presentations on tuberculosis. Here are the abstracts of a few of the talks. The first item received news coverage and discusses two approved antibiotics that may prove effective in treating TB. Additional links to TB R&D News are included.
TB R&D Weekly Update: TDR Tuberculosis Strain Bank
This week we highlight an article looking at the TDR Tuberculosis Strain Bank and its utility. Additional links to TB R&D news are included.
Posted in Early Drug Development, Front Lines of TB R&D, TB News, Voices from the Fight to Stop Tuberculosis, WGND Podcast Series
TB R&D Weekly Update: Podcast Interview with Dr. Yossef Av-Gay
This week we interview Dr. Yossef Av-Gay and discuss his recently published paper, his contribution to TB drug discovery and the focus of his research. Dr. Av-Gay, a professor in the Division of Infectious Diseases at the University of British Columbia, recently published a paper in PNAS that provides evidence to that points to a specific protein that allows Mtb to bypass the body’s defenses. Additional TB R&D news links are included.
Posted in Early Drug Development, Front Lines of TB R&D, TB Drug Development, Uncategorized
TB R&D Weekly Update: Novel Compounds Screened for DS and MDR-TB
This week’s featured article from Bill Jacob’s lab looks at novel InhA (target of isoniazid (INH), a first-line TB drug) inhibitors and their ability to kill M. tuberculosis (M.tb) that is drug-sensitive, resistant and in dormant stage. Two compounds were identified that had significant bactericidal activity against M.tb: CD 39 and CD117. Additional links to TB R&D News are included.
TB R&D Weekly Update: P27-P55 Operon of Mtb and Drug Resistance
his week, we present an article from researchers from the Instituto de Biotecnologia and TB Control Program in Buenos Aires, Argentina. The article focuses on the P27-P55 operon which has been shown in mice to be essential for M. tuberculosis (M. tb) to survive in the host. Additional links to TB R&D news are included.
TB R&D Weekly Update: Potential Use of Polyether Ionophores Against TB
During this week’s TB R&D Weekly Update, we explore the potential of polyether ionophores as anti-tuberculosis agents in an article published in 2009 by Kevin, et al. Links to additional TB R&D News are included.
Posted in Early Drug Development, Front Lines of TB R&D, TB Drug Development, TB Treatment
TB R&D Weekly Update: Efflux and Rifampicin Resistance
This week we look again at the role of efflux pumps in resistance to anti-tuberculosis drugs. Louw, et al., sought to “demonstrate that the level of rifampicin resistance is defined by efflux, which regulates the intracellular concentration of rifampicin.” This is a shift from the current thinking in the field that rifampicin resistance is solely the result of mutations in the rpoB gene. The article entitled “Rifampicin Reduces Susceptibility to Ofloxacin in Rifampicin Resistant Mycobacterium tuberculosis through Efflux” was published ahead of print in the American Journal of Respiratory and Critical Care Medicine. Additional links to TB R&D News is included.
Posted in Early Drug Development, Front Lines of TB R&D, TB Drug Development, Voices from the Fight to Stop Tuberculosis, WGND Podcast Series
TB R&D Weekly Update: Podcast interview on TB Drug Tolerance and Efflux Pumps
The WGND had the opportunity to interview three researchers (Lalita Ramakrishnan, Paul Edelstein, and Christine Cosma) involved in the groundbreaking research on the role of efflux pumps in contributing to drug tolerance during TB treatment which was published in the April 1 issue of Cell. Additional links to TB R&D News are included.
TB R&D Weekly Update: Drugs Targeting MMP-1 May Reduce Lung Pathology Caused by TB
In this week’s article which was published online ahead of print, Elkington, et al., presents significant data to support the premise that M. tuberculosis infection drives proteolytic destruction of the lung matrix contributing to lung damage caused by TB and to the morbidity and mortality of TB. Additional links to TB R&D News are included.
-
You are currently browsing the archives for the Early Drug Development category.
-
Toppix TB News- TB, a neglected disease in Uganda 15 May 2013
- Dr. John: Medications, T.B, tinnitus 8 May 2013
- U.S. non-profit group to build tuberculosis center in Pyongyang 4 May 2013
- Predictors of tuberculosis (TB) and antiretroviral (ARV) medication... 26 Apr 2013
- Multidrug-resistant tuberculosis (MDR-TB): an interview with Dr.... 26 Apr 2013
